Invited commentary: Sex-steroid hormones and qt-interval duration

American Journal of Epidemiology

Volumn 174, Issue 4, 2011, Pages 412-415

  Van Noord, Charlotte ^a   Rodenburg, Eline M ^a,b   Stricker, Bruno H C ^a,b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Inspectorate for Health Care   (Netherlands)

Author keywords

Gonadal steroid hormones; long QT syndrome; testosterone

Indexed keywords

CYTOCHROME P450 3A4; DIGOXIN; PLACEBO; POTASSIUM CHANNEL; POTASSIUM CHANNEL HERG; TESTOSTERONE;

CARDIOLOGY; MOLECULAR ANALYSIS; SEX HORMONE; SEX-RELATED DIFFERENCE; STEROID;

ATRIOVENTRICULAR JUNCTION ARRHYTHMIA; CONGESTIVE HEART FAILURE; HEART REPOLARIZATION; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; LONG QT SYNDROME; POINT MUTATION; POSTMENOPAUSE; PROTEIN EXPRESSION; QT INTERVAL; RETROSPECTIVE STUDY; REVIEW; SEX DIFFERENCE; SUDDEN DEATH;

ARRHYTHMIAS, CARDIAC; ATHEROSCLEROSIS; DEATH, SUDDEN, CARDIAC; ELECTROCARDIOGRAPHY; FEMALE; GONADAL STEROID HORMONES; HEALTH SURVEYS; HUMANS; LONG QT SYNDROME; MALE; NUTRITION SURVEYS; POSTMENOPAUSE; RISK FACTORS; SEX FACTORS; TESTOSTERONE; UNITED STATES;

EID: 80051494389     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwr170     Document Type: Review

References (48)

1. Myerburg RJ, Kessler KM, Castellanos A. Sudden cardiac death: epidemiology, transient risk, and intervention assessment. Ann Intern Med. 1993;119(12):1187-1197. (Pubitemid 23361449)
2. Myerburg RJ, Interian A Jr, Mitrani RM, et al. Frequency of sudden cardiac death and profiles of risk. Am J Cardiol. 1997; 80(5B):10F-19F. (Pubitemid 27377820)
3. Gorgels AP, Gijsbers C, de Vreede-Swagemakers J, et al. Out-of-hospital cardiac arrest-the relevance of heart failure. The Maastricht Circulatory Arrest Registry. Eur Heart J. 2003;24(13):1204-1209. (Pubitemid 36834636)
4. Josephson M, Wellens HJ. Implantable defibrillators and sudden cardiac death. Circulation. 2004;109(22): 2685-2691. (Pubitemid 38737911)
5. Straus SM, Kors JA, De Bruin ML, et al. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. J Am Coll Cardiol. 2006;47(2):362-367. (Pubitemid 43063255)
6. Keating MT, Sanguinetti MC. Molecular and cellular mechanisms of cardiac arrhythmias. Cell. 2001;104(4): 569-580. (Pubitemid 32201951)
7. Lasser KE, Allen PD, Woolhandler SJ, et al. Timing of new black box warnings and withdrawals for prescription medications. JAMA. 2002;287(17):2215-2220. (Pubitemid 34441937)
8. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350(10):1013-1022. (Pubitemid 38269278)
9. Al-Khatib SM, LaPointe NM, Kramer JM, et al. What clinicians should know about the QT interval. JAMA. 2003; 289(16):2120-2127. (Pubitemid 37430214)
10. Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. Heart. 2003;89(11):1363-1372. (Pubitemid 37311108)
11. Bazett H. An analysis of the time relationship of electrograms. Heart. 1920;7:353-370.
12. Abi-Gerges N, Philp K, Pollard C, et al. Sex differences in ventricular repolarization: from cardiac electrophysiology to torsades de pointes. Fundam Clin Pharmacol. 2004;18(2): 139-151. (Pubitemid 38491286)
13. Rautaharju PM, Zhou SH, Wong S, et al. Sex differences in the evolution of the electrocardiographic QT interval with age. Can J Cardiol. 1992;8(7):690-695.
14. McCammon R. A longitudinal study of electrocardiographic intervals in healthy children. Acta Pediatr. 1960;50(126): 3-54.
15. Stramba-Badiale M, Spagnolo D, Bosi G, et al. Are gender differences in QTc present at birth? MISNES Investigators. Multicenter Italian Study on Neonatal Electrocardiography and Sudden Infant Death Syndrome. Am J Cardiol. 1995; 75(17):1277-1278.
16. Bidoggia H, Maciel JP, Capalozza N, et al. Sex differences on the electrocardiographic pattern of cardiac repolarization: possible role of testosterone. Am Heart J. 2000;140(4): 678-683.
17. Malkin CJ, Morris PD, Pugh PJ, et al. Effect of testosterone therapy on QT dispersion in men with heart failure. Am J Cardiol. 2003;92(10):1241-1243. (Pubitemid 37377847)
18. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363(2):109-122.
19. Zhang Y, Ouyang P, Post WS, et al. Sex-steroid hormones and electrocardiographic QT-interval duration: findings from the Third National Health and Nutrition Examination Survey and the Multi-Ethnic Study of Atherosclerosis. Am J Epidemiol. 2011;174(4):403-411.
20. van Noord C, Dö rr M, Sturkenboom MC, et al. The association of serum testosterone levels and ventricular repolarization. Eur J Epidemiol. 2010;25(1):21-28.
21. Stramba-Badiale M, Crotti L, Goulene K, et al. Electrocardiographic and genetic screening for long QT syndrome: results from a prospective study on 44,596 neonates (abstract). Circulation. 2007;116(suppl II):II-377.
22. Schwartz PJ, Priori SG, Napolitano C. How really rare are rare diseases? The intriguing case of independent compound mutations in the long QT syndrome. J Cardiovasc Electrophysiol. 2003;14(10):1120-1121. (Pubitemid 37412092)
23. Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long-QT syndrome. N Engl J Med. 2003;348(19): 1866-1874. (Pubitemid 36532312)
24. Crotti L, Celano G, Dagradi F, et al. Congenital long QT syndrome. Orphanet J Rare Dis. 2008;3:18.
25. Lehmann MH, Timothy KW, Frankovich D, et al. Age-gender influence on the rate-corrected QT interval and the QT-heart rate relation in families with genotypically characterized long QT syndrome. J Am Coll Cardiol. 1997;29(1):93-99. (Pubitemid 27028725)
26. Zareba W, Moss AJ, Locati EH, et al. Modulating effects of age and gender on the clinical course of long QT syndrome by genotype. International Long QT Syndrome Registry. J Am Coll Cardiol. 2003;42(1):103-109. (Pubitemid 36760769)
27. Locati EH, Zareba W, Moss AJ, et al. Age-and sex-related differences in clinical manifestations in patients with congenital long-QT syndrome: findings from the International LQTS Registry. Circulation. 1998;97(22):2237-2244. (Pubitemid 28265385)
28. Makkar RR, Fromm BS, Steinman RT, et al. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA. 1993;270(21):2590-2597. (Pubitemid 23346699)
29. Bednar MM, Harrigan EP, Ruskin JN. Torsades de pointes associated with nonantiarrhythmic drugs and observations on gender and QTc. Am J Cardiol. 2002;89(11):1316-1319. (Pubitemid 34606900)
30. Kawasaki R, Machado C, Reinoehl J, et al. Increased propensity of women to develop torsades de pointes during complete heart block. J Cardiovasc Electrophysiol. 1995; 6(11):1032-1038.
31. Eiferman C, Chanson P, Cohen A, et al. Torsade de pointes and Q-T prolongation in secondary hypothyroidism. Lancet. 1988;2(8603):170-171.
32. Kumar A, Bhandari AK, Rahimtoola SH. Torsade de pointes and marked QT prolongation in association with hypothyroidism. Ann Intern Med. 1987;106(5):712-713. (Pubitemid 17067992)
33. van Noord C, van der Deure WM, SturkenboomMC, et al. High free thyroxine levels are associated with QTc prolongation in males. J Endocrinol. 2008;198(1):253-260.
34. van Noord C, Sturkenboom MC, Straus SM, et al. Populationbased studies of antithyroid drugs and sudden cardiac death. Br J Clin Pharmacol. 2009;68(3):447-454.
35. Lehmann MH, Frankovich D, Baga JJ, et al. Does subclinical hypothyroidism explain the increased susceptibility of women to torsades de pointes? Am J Cardiol. 1997;79(7):963-965. (Pubitemid 27197934)
36. Drici MD, Knollmann BC, Wang WX, et al. Cardiac actions of erythromycin: influence of female sex. JAMA. 1998; 280(20):1774-1776. (Pubitemid 28536879)
37. Roden DM. Cellular basis of drug-induced torsades de pointes. Br J Pharmacol. 2008;154(7):1502-1507.
38. Sanguinetti MC, Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia. Nature. 2006;440(7083): 463-469.
39. van Noord C, Sturkenboom MC, Straus SM, et al. Noncardiovascular drugs that inhibit hERG-encoded potassium channels and risk of sudden cardiac death. Heart. 2011;97(3): 215-220.
40. Roden DM. Antiarrhythmic drugs: from mechanisms to clinical practice. Heart. 2000;84(3):339-346.
41. Tanaka E. Gender-related differences in pharmacokinetics and their clinical significance. J Clin Pharm Ther. 1999; 24(5):339-346. (Pubitemid 29520783)
42. Shuba YM, Degtiar VE, Osipenko VN, et al. Testosteronemediated modulation of HERG blockade by proarrhythmic agents. Biochem Pharmacol. 2001;62(1):41-49. (Pubitemid 32488976)
43. Ebert SN, Liu XK, Woosley RL. Female gender as a risk factor for drug-induced cardiac arrhythmias: evaluation of clinical and experimental evidence. J Womens Health. 1998; 7(5):547-557.
44. Pham TV, Rosen MR. Sex, hormones, and repolarization. Cardiovasc Res. 2002;53(3):740-751. (Pubitemid 34175265)
45. Wolbrette D. Gender differences in the proarrhythmic potential of QT-prolonging drugs. Curr Womens Health Rep. 2002;2(2):105-109.
46. Kannel WB, Wilson PW, D'Agostino RB, et al. Sudden coronary death in women. Am Heart J. 1998;136(2):205-212. (Pubitemid 28368840)
47. Schatzkin A, Cupples LA, Heeren T, et al. Sudden death in the Framingham Heart Study: differences in incidence and risk factors by sex and coronary disease status. Am J Epidemiol. 1984;120(6):888-899. (Pubitemid 15216802)
48. Albert CM, McGovern BA, Newell JB, et al. Sex differences in cardiac arrest survivors. Circulation. 1996;93(6):1170-1176. (Pubitemid 26087020)